US pharma giant Pfizer said that it will invest $95 million in Valneva, a French specialty vaccine company, for an 8.1% stake. The two firms have signed an equity subscription agreement in this connection. Besides, they have amended the terms of their collaboration and license agreement for VLA15, a vaccine candidate for Lyme disease. Pfizer […]
Pfizer said that PF-06928316 (RSVpreF), its respiratory syncytial virus (RSV) vaccine candidate, has been granted breakthrough therapy designation from the US Food and Drug Administration (FDA). The breakthrough therapy designation is for the use of the vaccine candidate in the prevention of lower respiratory tract disease caused by RSV in patients aged 60 years or […]
Pfizer has secured breakthrough therapy designation for its respiratory syncytial virus (RSV) vaccine candidate — PF-06928316 (RSVpreF) from the US Food and Drug Administration (FDA) for the prevention of RSV-associated lower respiratory tract illness in infants from the time of birth up to six months by active immunization of pregnant women. According to Pfizer, the […]
US pharma giant Pfizer has initiated four phase 3 clinical trials within its present pipeline of investigational vaccines. The company’s 20vPnC, which is a 20-valent pneumococcal polysaccharide conjugate vaccine candidate, will be evaluated in two phase 3 trials NCT04382326 and NCT04379713. Both the late-stage trials will evaluate a four-dose series in infants starting at the […]